🇺🇸

US SEC Filing Intelligence

· daily

US SEC Filings Daily Market Digest — May 20, 2026

Today's filings reveal a bifurcated market with strong growth in select industrials and tech (Analog Devices +37% YoY, Dorian LPG +102% YoY, CAVA +32% YoY) contrasting with sharp declines in energy and small-cap names (PrimeEnergy -52.5% net income, Cavitation Technologies -97.5% revenue). The most critical development is the proposed $3.4B transformational merger of Sachem Capital with IRG, which could create a top-10 industrial REIT but carries significant execution risk. Insider activity is notably absent across filings, but capital allocation patterns show a clear preference for debt reduction and buybacks over dividends. The SPAC market shows renewed activity with FutureCorp's $200M IPO filing, while the crypto space sees institutional validation with Morgan Stanley's Solana and Ethereum trust filings. Portfolio-level trends indicate margin compression in consumer-facing names (CAVA, Hasbro) despite revenue growth, while semiconductor and energy shipping sectors demonstrate exceptional operating leverage.

25 high priority 25 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — May 20, 2026

This batch of 50 S&P 500 Consumer Discretionary filings reveals a deeply bifurcated landscape. On the positive side, **e.l.f. Beauty** reported exceptional 35% YoY revenue growth and **VF Corp** showed a strong Americas turnaround (+10% C$ ex-Dickies), while **Flex Ltd** posted 8.1% revenue growth driven by cloud infrastructure. However, these bright spots are overshadowed by widespread margin compression and deteriorating profitability. Key financial indicators show 5 companies with net losses widening by over 100% YoY and 3 companies with revenue declines. Insider activity is notably absent, with no major buying or selling signals from management across the filings. Capital allocation trends are defensive, with **Starbucks** completing $1.32B in debt buybacks and **United Fire Group** extending share repurchase authority, while dividend policies remain stable. The most critical development is **Six Flags** entering a cooperation agreement with activist investor H Partners, signaling potential operational changes in the entertainment sector. Sector-wide risks include tariff-driven cost pressures in imported goods (retail/apparel), potential recession dampening discretionary spending, and rising input costs in automotive and consumer electronics. **FG Merger II Corp**'s planned merger with modular housing company Boxabl highlights a growing SPAC trend in housing innovation.

22 high priority 28 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — May 20, 2026

The 50 filings for the S&P 500 Healthcare stream reveal a sector bifurcated between large-cap innovators executing capital market maneuvers and small/mid-cap firms facing acute financial distress. Eli Lilly and Gilead Sciences raised a combined ~$12 billion in debt, signaling a period of aggressive M&A and pipeline investment, while Roivant Sciences posted a massive $2.25 billion settlement gain but saw R&D expenses surge 37%. Conversely, several micro-cap biotechs (e.g., Klotho Neurosciences, Lifeward) reported widening net losses of 555% and 125% YoY, respectively, highlighting a cash-burn crisis. A key period-over-period trend is the divergence in revenue performance: Pacira BioSciences reported record revenue with 5-21% product growth, while Scilex Holding grew revenue 72% but saw its net loss balloon 75% due to non-cash charges. Insider activity was notably absent from the filings, but proxy fights (Pacira vs. DOMA) and shareholder dissent (Amgen's independent chairman proposal rejected 4.6:1) signal governance tensions. Capital allocation is a mixed bag, with Zoetis maintaining a stable dividend and Stryker executing a planned CFO transition, while distressed firms like Renewal Fuels and Citrine Global burn cash with no path to profitability. The overarching theme is a 'flight to quality' where only companies with strong balance sheets and clear catalysts (e.g., Roivant's brepocitinib NDA) are positioned to thrive.

21 high priority 29 medium 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — May 20, 2026

This intelligence stream analyzes 8 DEF 14A proxy filings for the 2026 annual meeting season, revealing a concentrated focus on capital structure management and governance transitions. A dominant theme is the prevalence of reverse stock split proposals (Longeveron, Oragenics) and share issuance authorizations (Blink Charging, MSC Income Fund), signaling that several small-cap and micro-cap companies are actively managing stock price compliance or raising capital. Insider trading activity is notably absent across all filings, providing no direct management conviction signals. Period-over-period comparisons are largely unavailable as these proxy statements focus on governance proposals rather than financial performance. However, the filings reveal a clear pattern of companies seeking to increase equity incentives (Blink Charging, Workhorse) and authorize below-NAV share sales (MSC Income Fund), indicating a focus on retaining talent and accessing capital markets. The most critical development is the high concentration of annual meetings in late June 2026, creating a catalyst calendar for governance votes that could impact stock liquidity and dilution. Overall, the filings suggest a cautious capital allocation environment with an emphasis on survival and flexibility rather than aggressive growth.

8 high priority 8 total filings
· daily

US IPO Pipeline SEC S-1 Filings — May 20, 2026

The IPO pipeline on May 20, 2026, is dominated by high-profile, high-growth names, including SpaceX and Medline, alongside a traditional SPAC (FutureCorp) and a nuclear energy play (Deep Fission). A key theme is the prevalence of secondary offerings and insider monetization, most notably Medline's filing by pre-IPO owners (Blackstone, Carlyle, H&F) and SpaceX's dual-class structure ensuring Elon Musk's control. The Skyworks/Qorvo S-4 filing, while not an IPO, signals significant M&A activity in the semiconductor sector, with a $1.55B debt exchange offer. Period-over-period data reveals strong revenue growth trajectories, with Medline boasting an 18% CAGR since inception and Picard Medical showing a 15% YoY revenue increase. However, dilution risks are acute: FutureCorp's sponsor acquired founder shares at $0.004 vs. the $10.00 IPO price, and Medline's secondary offering could pressure the stock. The overall sentiment is mixed, balancing high-growth opportunities against significant dilution and governance risks.

6 high priority 6 total filings
· daily

Global High-Priority Regulatory Events — May 20, 2026

This intelligence stream reveals a bifurcated market landscape on May 20, 2026, characterized by severe distress in small-cap and micro-cap companies, counterbalanced by robust growth and strategic positioning in larger, more established firms. The most critical developments include a delisting and Chapter 11 bankruptcy filing by Society Pass Inc., alongside a wave of negative earnings surprises and widening losses across a cohort of micro-cap entities (Powerdyne, Renewal Fuels, AppYea, Starfighters Space). Conversely, Analog Devices reported a standout 37% YoY revenue surge, while Apollo Hospitals delivered 18% top-line growth and a 31% EBITDA increase, signaling strong sector-specific demand. A significant trend is the aggressive capital market activity, with multiple SPAC IPOs (FutureCorp Space, Deep Fission) and crypto-asset trust filings (Morgan Stanley for Solana and Ethereum) indicating sustained institutional appetite for thematic and speculative assets. Period-over-period data shows a clear pattern of revenue growth failing to translate to profitability for many growth-stage companies, with operating expenses and non-cash charges eroding bottom lines. Insider activity was notably absent, but capital allocation decisions—such as debt refinancing by Avista Corp. and a $3.75B credit facility for Williams Companies—point to a focus on liquidity management. The overall sentiment is mixed, with high materiality events concentrated in bankruptcy, regulatory actions, and transformative M&A, demanding immediate attention from event-driven investors.

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — May 20, 2026

The 50 filings reveal a bifurcated market: growth companies like Analog Devices (+37% YoY revenue) and AEVEX Corp (swinging to $21M net income from a $27M loss) are thriving, while a broad swath of micro-cap and pre-revenue firms face severe liquidity crises, with 15+ companies reporting widening net losses and cash burn. Period-over-period trends show revenue growth concentrated in industrial, defense, and niche tech, while consumer-facing and energy-exposed firms struggle. Insider activity is sparse, but management teams at distressed companies are issuing dilutive securities at alarming rates. Capital allocation is defensive—debt reduction and equity raises dominate, with only a few firms (e.g., Immunovant) strengthening balance sheets via offerings. The most critical development is the wave of going-concern warnings and negative equity positions across 10+ filings, signaling potential bankruptcies. Portfolio-level patterns include margin compression in manufacturing (EnerSys -100 bps gross margin) and a surge in impairment charges (Heritage Distilling $62.1M, Haemonetics $86.5M).

50 high priority 50 total filings
· daily

US SEC Trading Suspension Halt Orders — May 20, 2026

The May 20, 2026 trading suspension intelligence stream reveals a concentrated cluster of 6 Nasdaq-listed micro-cap companies facing regulatory actions, with 50% of filings involving actual delisting notices (SOCIETY PASS, TOMI Environmental) and the remainder at various stages of non-compliance (Singularity Future, Socket Mobile, Aimei Health). This represents a significant escalation compared to prior periods, which typically saw 1-2 such events per day, indicating a potential tightening of Nasdaq enforcement or a broader distress cycle among sub-$1.00 micro-cap issuers. Period-over-period comparisons show that 4 of 6 companies have been non-compliant for over 6 months, with Singularity Future receiving its second 180-day extension—a pattern suggesting prolonged structural weakness rather than temporary volatility. No insider transactions were reported across any of the filings, which is notable given the severity of the events, implying management teams may be unable or unwilling to signal confidence through open-market purchases. The 3 companies with ongoing compliance periods (Socket Mobile, Singularity Future, Aimei Health) face deadlines between May and November 2026, creating a catalyst calendar for potential reversals or delistings. The complete absence of forward-looking financial guidance, capital allocation activity (dividends, buybacks), or positive operational metrics across all 6 filings paints a picture of entities in survival mode, with bankruptcy and illiquidity as material tail risks.

6 high priority 6 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — May 20, 2026

The 47 filings from May 20, 2026, reveal a bifurcated corporate landscape: a surge in distress signals (bankruptcies, delistings, liquidity crises) is concentrated in small-cap and pre-revenue tech/healthcare names, while larger, established firms are proactively refinancing debt and optimizing capital structures. Key period-over-period trends show a stark contrast, with companies like Curtiss-Wright reporting 12% YoY revenue growth but a 4.4% decline in net income, highlighting margin pressure, while Golden Minerals improved its net loss by 50% YoY but faces a severe cash crunch. The most critical developments include the Chapter 11 filing of Society Pass, multiple Nasdaq delisting notices (TOMI, Socket Mobile, Singularity Future), and a transformative but high-risk merger for Envirotech Vehicles. Portfolio-level patterns reveal a 'flight to quality' in debt markets, with investment-grade issuers like Gilead and Williams Companies accessing large, low-cost facilities, while distressed firms are forced into dilutive equity or debt-for-equity swaps. The overall market implication is one of increasing credit divergence, where access to capital is a key differentiator between survival and failure.

47 high priority 47 total filings
· daily

US Executive Officer Management Changes SEC — May 20, 2026

The 50 filings reveal a significant wave of leadership transitions across US equities, with CEO departures at Choice Hotels, NusaTrip, and Wendy's, alongside CFO changes at Philip Morris, Skillz, and Caleres, among others. Period-over-period data from ChoiceOne Financial shows adjusted net income dropping sharply to $1.0M in Q1 2026 from $28.2M in full-year 2025, signaling a concerning trend in regional banking performance. Insider activity is limited, but notable shareholder dissent on compensation plans at Iridium (13.2% against say-on-pay) and Insperity (7.7% against incentive plan) suggests governance tensions. Forward-looking guidance reaffirmations at Choice Hotels, Schrodinger, and Turtle Beach provide stability amid leadership changes, while BrightSpire Capital's CEO extension with reduced bonus targets signals a potential cost-control strategy. Capital allocation remains steady with dividend declarations at Iridium and Global Medical REIT, but the lack of buyback activity across filings suggests a cautious reinvestment posture. The most critical developments include the termination for cause of NusaTrip's CEO and CFO, which raises governance red flags, and the orderly succession at Clean Harbors with its founder retiring after 46 years. Overall, the digest points to a market in transition, with leadership changes concentrated in mid-cap and small-cap firms, requiring close monitoring of execution risks and strategic shifts.

50 high priority 50 total filings
· daily

US Corporate Board Director Changes SEC Filings — May 20, 2026

This batch of 50 filings covering the period May 20, 2026, reveals a significant wave of C-suite and board-level transitions, with CEO changes at major firms like Wendy's and Choice Hotels, and CFO appointments at Philip Morris, Skillz, and Caleres. The data shows a clear trend of companies appointing internal successors or returning former executives, suggesting a preference for continuity. Forward-looking statements, including reaffirmed guidance at Choice Hotels and Turtle Beach, indicate that leadership changes are not expected to disrupt near-term financial performance. Insider activity is limited, but the extension of CEO Michael Mazzei's contract at BrightSpire Capital with reduced compensation targets presents a unique mixed signal. Overall, the market is absorbing a high volume of governance changes, which could create volatility but also opportunities for investors focused on strategic realignment.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — May 20, 2026

The three filings reveal a bifurcated M&A landscape: strategic bolt-on acquisitions in defense tech (Red Cat/Quaze) and manufacturing capacity expansion (XPEL) contrast with a purely procedural SPAC unit separation (QDRO). Red Cat's acquisition of Quaze Technologies addresses a critical operational bottleneck in drone autonomy—wireless recharging—with immediate cross-domain applicability, while XPEL's $110M investment in US and China manufacturing capacity signals confidence in long-term demand, backed by reaffirmed mid-20% operating margin targets for 2028. The QDRO filing offers no financial or operational content, serving only as a reminder of the SPAC market's ongoing technical adjustments. Across the two material filings, both companies are deploying capital for growth rather than shareholder returns, with no dividends or buybacks disclosed. Insider trading activity was absent from all three filings, limiting conviction signals. The key portfolio-level theme is capital deployment into tangible assets (IP, facilities) to capture vertical integration and operational efficiency gains.

3 high priority 3 total filings
· monthly

US Pre-Market SEC Filings Roundup — May 20, 2026

Overnight filings reveal a bifurcated market, with high-growth tech and LPG shipping surging while traditional energy, real estate, and cash-burning pre-revenue companies deteriorate sharply. Period-over-period data shows Analog Devices leading with 37% revenue growth and 111% EPS expansion, while PrimeEnergy Resources saw a 52.5% net income decline. Insider activity is limited, but restructuring and M&A themes dominate: Select Medical's $16/share buyout, Sachem Capital's $3.4B industrial REIT combination, and Medline's secondary offering signal significant corporate activity. Several micro-cap companies (Cavitation Technologies, Cyber Enviro-Tech, Starfighters Space) face deepening losses and cash crunches. The most actionable themes are the semiconductor recovery (ADI +37% YoY, E20 Capital's $1.07B tech-heavy 13F), the LPG shipping boom (Dorian LPG +102% revenue), and the rising risk of delistings/bankruptcies in distressed micro-caps.

25 high priority 25 medium 50 total filings
· daily

NME Blockbuster Approvals — May 19, 2026

During the single-day period of May 19, 2026, the FDA issued one approval classified as 'Other' (FALLBACK type), with no NMEs, biosimilars, or label expansions recorded. The sole event was the NME approval of SONROTOCLAX (BEGALZI) from BEONE MEDICINES USA, granted Priority Review and Orphan Drug designations—a bullish signal for a rare disease asset. However, the lack of disclosed peak sales estimates, exclusivity terms, or pricing power limits the immediate commercial conviction. The dominant theme is a targeted rare disease NME launch, but the sparse approval volume offers no sector-wide therapeutic area clustering. Key watch items include the undisclosed market positioning and the absence of near-term catalysts beyond the approval itself.

1 total filings
· daily

Big Pharma Approvals — May 19, 2026

During this period, the FDA issued three label expansion approvals, all classified as 'FALLBACK' type, with zero NMEs, biosimilars, or standard label expansions. The dominant therapeutic area is immunology/inflammation, with Genentech Inc securing two approvals for its anti-PD-L1 franchise (TECENTRIQ HYBREZA and TECENTRIQ) and AstraZeneca AB obtaining one for its anti-IL-5Rα biologic FASENRA (benralizumab). The highest-conviction signal is the dual approval for Genentech's atezolizumab formulations, which strengthens its competitive position in oncology by offering both IV and subcutaneous delivery options. However, the lack of NME approvals and the 'FALLBACK' designation—which may indicate supplemental or minor label updates—limits the commercial upside and catalyst intensity. Key risk: without disclosed indication details or peak sales estimates, the materiality of these expansions remains uncertain, and investors should watch for payer coverage decisions and competitive dynamics in the PD-L1 and severe asthma markets.

3 total filings
· daily

Orphan Drug Approvals — May 19, 2026

This digest covers a single Orphan Drug Approval on May 19, 2026, with no NMEs, biosimilars, or label expansions recorded. The sole event is the FDA NME approval of SONROTOCLAX (BEGALZI) by BEONE MEDICINES USA, granted Priority Review and Orphan Drug designation, representing a high-conviction bullish signal for a novel therapy in a rare disease setting. The absence of other approvals limits therapeutic area clustering, but the single approval underscores BEONE MEDICINES USA's execution capability in bringing an NME to market with regulatory incentives. Key watch items include commercial launch dynamics and pricing strategy, as the drug’s peak sales and exclusivity details remain undisclosed, creating uncertainty around revenue potential.

1 total filings
· daily

New Drug Approvals (Original) — May 19, 2026

The May 19, 2026 FDA approval stream is dominated by biosimilar and generic approvals (11 of 12), with zero NMEs and one label expansion, signaling a period of market access expansion rather than novel drug innovation. The highest-conviction signal is the NME approval of SONROTOCLAX (BEGALZI) by BEONE MEDICINES USA, which received Priority Review and Orphan Drug designations, indicating a high-value, targeted therapy with strong regulatory endorsement. The biosimilar approval of GALLIUM GA-68 GOZOTETIDE by IONETIX via an unusual ANDA pathway introduces a lower-cost diagnostic alternative in the radiopharmaceutical space, bullish for the entrant but bearish for the undisclosed originator. The absence of NMEs and the high volume of biosimilar/generic approvals (10 of 12) suggest a market focus on cost containment and competitive erosion, with no new therapeutic area clusters emerging. Key watch items include the commercial launch of SONROTOCLAX and formulary access decisions for IONETIX’s diagnostic agent, as well as the IRA exposure of any small-molecule biosimilars approved this period.

12 total filings
· daily

New Federal Contractors — May 19, 2026

The sole contract recorded for May 19, 2026, is a $116.2M cost-plus-award-fee delivery order awarded to Booz Allen Hamilton by the General Services Administration (GSA) FEDSIM for civil-military support services. This is a civilian agency award with no defense-related component, and the aggregate obligation of $116.2M carries a neutral signal strength of 5/10. The contract's negative outlay (-$287K) and minimal subawards suggest negligible revenue recognized to date, limiting near-term financial impact. Key risks include award fee variability under cost-plus pricing and execution uncertainty given the low outlay, while the fully competed nature confirms Booz Allen's competitive positioning in professional support services.

1 total filings
· daily

Significant Contract Modifications ($10M+) — May 19, 2026

The single contract analyzed for May 19, 2026, is a $116.2M cost-plus-award-fee delivery order awarded to Booz Allen Hamilton by GSA FEDSIM for civil-military support services, representing a purely civilian obligation with zero defense exposure. The contract's neutral signal strength (5/10) and low materiality (3/10) are driven by a negative outlay (-$287K) and minimal subawards ($100K), indicating negligible revenue recognized to date and limited near-term financial impact. The award confirms sustained demand for interagency professional support services, but the cost-plus-award-fee structure introduces margin uncertainty tied to performance metrics. Key watch items include monitoring future outlay amounts to validate revenue recognition and tracking potential modifications beyond the March 2024 end date.

1 total filings